ProCE Banner Activity

CALIBRATE: Wk 54 Primary Analysis of Long-Acting Subcutaneous Lenacapavir in Treatment-Naive Patients

Slideset Download
Conference Coverage
Two regimens featuring a subcutaneous lenacapavir backbone administered every 6 months conferred complete virologic suppression in 85% to 90% of patients at Week 54.

Released: February 18, 2022

Expiration: February 17, 2023

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Cepheid

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck & Co., Inc.

ViiV Healthcare